BACKGROUND: Standard therapy for stage II/III rectal cancer consists of a fluoropyrimidine and radiation therapy followed by surgery. Preclinical data demonstrated that bortezomib functions as a radiosensitizer in colorectal cancer models. The purpose of this study was to determine the maximum tolerated dose (MTD) of bortezomib in combination with chemotherapy and radiation. PATIENTS AND METHODS: Patients with locally advanced rectal adenocarcinomas, as staged by endoscopic ultrasound, were eligible. Bortezomib was administered on days 1, 4, 8, and 11 every 21 days for 2 cycles with 5-fluorouracil at 225 mg/m2/day continuously and 50.4 Gy of radiation. Dose escalation of bortezomib was conducted via a standard 3 + 3 dose escalation design. A subset of patients underwent serial tumor biopsies for correlative studies. RESULTS: Nine patients in 2 dose cohorts were enrolled. Diarrhea was the principal dose-limiting toxicity and occurred at the 1.0-mg/m2 dose level. There was no clear evidence of suppression of nuclear factor-kappaB target gene expression in biopsy samples. CONCLUSION: The MTD of bortezomib in combination with chemotherapy and radiation may be below a clinically relevant dose, limiting the clinical applicability of this combination. Performing biopsies before and during irradiation for determining gene expression in response to radiation therapy is feasible.
BACKGROUND: Standard therapy for stage II/III rectal cancer consists of a fluoropyrimidine and radiation therapy followed by surgery. Preclinical data demonstrated that bortezomib functions as a radiosensitizer in colorectal cancer models. The purpose of this study was to determine the maximum tolerated dose (MTD) of bortezomib in combination with chemotherapy and radiation. PATIENTS AND METHODS: Patients with locally advanced rectal adenocarcinomas, as staged by endoscopic ultrasound, were eligible. Bortezomib was administered on days 1, 4, 8, and 11 every 21 days for 2 cycles with 5-fluorouracil at 225 mg/m2/day continuously and 50.4 Gy of radiation. Dose escalation of bortezomib was conducted via a standard 3 + 3 dose escalation design. A subset of patients underwent serial tumor biopsies for correlative studies. RESULTS: Nine patients in 2 dose cohorts were enrolled. Diarrhea was the principal dose-limiting toxicity and occurred at the 1.0-mg/m2 dose level. There was no clear evidence of suppression of nuclear factor-kappaB target gene expression in biopsy samples. CONCLUSION: The MTD of bortezomib in combination with chemotherapy and radiation may be below a clinically relevant dose, limiting the clinical applicability of this combination. Performing biopsies before and during irradiation for determining gene expression in response to radiation therapy is feasible.
Authors: S M Russo; J E Tepper; A S Baldwin; R Liu; J Adams; P Elliott; J C Cusack Journal: Int J Radiat Oncol Biol Phys Date: 2001-05-01 Impact factor: 7.038
Authors: Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab Journal: N Engl J Med Date: 2004-10-21 Impact factor: 91.245
Authors: Carter Van Waes; Angela A Chang; Peter F Lebowitz; Colleen H Druzgal; Zhong Chen; Yusri A Elsayed; John B Sunwoo; Susan F Rudy; John C Morris; James B Mitchell; Kevin Camphausen; David Gius; Julian Adams; Edward A Sausville; Barbara A Conley Journal: Int J Radiat Oncol Biol Phys Date: 2005-07-11 Impact factor: 7.038
Authors: J Adams; V J Palombella; E A Sausville; J Johnson; A Destree; D D Lazarus; J Maas; C S Pien; S Prakash; P J Elliott Journal: Cancer Res Date: 1999-06-01 Impact factor: 12.701
Authors: S Y Ngan; B H Burmeister; R Fisher; D Rischin; D J Schache; A Kneebone; J R MacKay; D Joseph; A Bell; D Goldstein Journal: Int J Radiat Oncol Biol Phys Date: 2001-07-15 Impact factor: 7.038
Authors: J G Izzo; X Wu; T-T Wu; P Huang; J-S Lee; Z Liao; J H Lee; M S Bhutani; W Hofstetter; D Maru; M-C Hung; J A Ajani Journal: Dis Esophagus Date: 2008-11-19 Impact factor: 3.429
Authors: Anastasia Ivanova; Gary L Rosner; Olga Marchenko; Tom Parke; Inna Perevozskaya; Yanping Wang Journal: Ther Innov Regul Sci Date: 2014-01 Impact factor: 1.778
Authors: Ibrahim Meteoglu; Ibrahim Halil Erdogdu; Pars Tuncyurek; Adil Coskun; Nil Culhaci; Muhan Erkus; Sabri Barutca Journal: Gastroenterol Res Pract Date: 2015-04-06 Impact factor: 2.260
Authors: Christopher D Lao; Judah Friedman; Christina I Tsien; Daniel P Normolle; Christopher Chapman; Yue Cao; Oliver Lee; Matt Schipper; Catherine Van Poznak; Daniel Hamstra; Theodore Lawrence; James Hayman; Bruce G Redman Journal: Radiat Oncol Date: 2013-08-21 Impact factor: 3.481